These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3930919)

  • 21. [Transdermal therapeutic systems].
    Primorac M; Odri S; Stupar M; Vuleta G
    Srp Arh Celok Lek; 1985 Oct; 113(10):893-900. PubMed ID: 3938572
    [No Abstract]   [Full Text] [Related]  

  • 22. Transdermal delivery system--a unique drug dosage form.
    Worden J
    N C Med J; 1983 Dec; 44(12):800-1. PubMed ID: 6420713
    [No Abstract]   [Full Text] [Related]  

  • 23. [Transdermal therapeutic systems. Possibilities and limitations].
    Groth H; Spuler A; Vetter W
    Dtsch Med Wochenschr; 1988 May; 113(20):819-21. PubMed ID: 3131097
    [No Abstract]   [Full Text] [Related]  

  • 24. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Management of transdermal therapeutics in perioperative care].
    Gentile A; Tran-Van D; Dardare E; Fritsch N; Benois A; Fontaine B
    Ann Fr Anesth Reanim; 2009 Apr; 28(4):311-20. PubMed ID: 19304449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal clonidine.
    Saad N; Rybak MJ
    Drug Intell Clin Pharm; 1986 Jan; 20(1):78. PubMed ID: 3943463
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetic interpretation of the plasma levels of clonidine following transdermal delivery.
    Guy RH; Hadgraft J
    J Pharm Sci; 1985 Sep; 74(9):1016-8. PubMed ID: 4067843
    [No Abstract]   [Full Text] [Related]  

  • 28. Transdermal clonidine for hypertension.
    Med Lett Drugs Ther; 1985 Oct; 27(700):95-6. PubMed ID: 4058369
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical efficacy of current transdermal drug delivery systems: a retrospective evaluation.
    Berba J; Banakar U
    Am Pharm; 1990 Nov; NS30(11):33-7, 40-1. PubMed ID: 2124411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
    Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
    Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceutical considerations of transdermal nitroglycerin delivery: the various approaches.
    Chien YW
    Am Heart J; 1984 Jul; 108(1):207-16. PubMed ID: 6428207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis, disposition and pharmacokinetics of nitroglycerin.
    Curry SH; Aburawi SM
    Biopharm Drug Dispos; 1985; 6(3):235-80. PubMed ID: 3929851
    [No Abstract]   [Full Text] [Related]  

  • 34. [Transdermal estradiol substitution in the postmenopause, individual dosage adjustment and effectiveness in the treatment of climacteric symptoms].
    Schenkel L; von Graffenried A
    Schweiz Rundsch Med Prax; 1987 Mar; 76(14):358-61. PubMed ID: 3589291
    [No Abstract]   [Full Text] [Related]  

  • 35. Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system.
    Karim A
    Angiology; 1983 Jan; 34(1):11-22. PubMed ID: 6401951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Transdermal therapeutics].
    Touitou E; Menczel E
    Harefuah; 1986 Apr; 110(7):356-9. PubMed ID: 3089890
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transdermal drug delivery and cutaneous metabolism.
    Guy RH; Hadgraft J; Bucks DA
    Xenobiotica; 1987 Mar; 17(3):325-43. PubMed ID: 3107225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Kinetics of a new patch for transdermal administration of 17 beta-estradiol].
    Rohr UD; Nauert C; Ehrly AM
    Zentralbl Gynakol; 1995; 117(10):531-9. PubMed ID: 7491836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen replacement therapy and the estraderm transdermal system.
    Youngkin EQ
    Nurse Pract; 1990 May; 15(5):19-26, 31. PubMed ID: 2342664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.